[COVID-19 vaccine and anticoagulation patients at high cardiovascular risk. SEMERGEN recommendations]

Semergen. 2021 Jan-Feb;47(1):1-3. doi: 10.1016/j.semerg.2020.12.005. Epub 2021 Jan 2.
[Article in Spanish]
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Anticoagulants / adverse effects
  • BNT162 Vaccine
  • COVID-19 Vaccines
  • COVID-19*
  • Cardiovascular Diseases* / epidemiology
  • Cardiovascular Diseases* / prevention & control
  • Heart Disease Risk Factors
  • Humans
  • RNA, Messenger
  • Risk Factors
  • SARS-CoV-2

Substances

  • Anticoagulants
  • COVID-19 Vaccines
  • RNA, Messenger
  • BNT162 Vaccine